ArticleRheumatology international2019
Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina.
Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The association between primary Sjogren's syndrome and non-Hodgkin's lymphoma: a systematic review and meta-analysis of cohort studies.Clinical rheumatology · 2024Pooled it
- Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Autoimmune disease and oral squamous cell carcinoma: A systematic review.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2021Pooled it
- Female cancer incidence before and after diagnosis of primary Sjögren's disease: A retrospective cohort study.Journal of translational autoimmunity · 2026Article
- High incidence of lymphoma in Sjögren's disease: predictors and mortality implications in a prospective cohort study.Rheumatology international · 2025Observational
- Evaluation of the Incidence of Malignancy in Sjögren's Syndrome: A Single-Center Study From Turkey.Cureus · 2025Article
- Epidemiology of Sjögren syndrome.Nature reviews. Rheumatology · 2024Review
- The global burden of breast cancer in women from 1990 to 2030: assessment and projection based on the global burden of disease study 2019.Frontiers in oncology · 2024Article
- Chronological interplay, clinical features, and treatments among patients with cancer and primary Sjögren's syndrome.Cancer immunology, immunotherapy : CII · 2023Article
- The risk of developing non-Hodgkin lymphoma and the mortality rate in primary Sjögren's syndrome: a single-centre, retrospective cohort study.Rheumatology international · 2023Article
- Causal associations of Sjögren's syndrome with cancers: a two-sample Mendelian randomization study.Arthritis research & therapy · 2023Article
- The risk of cancer in patients with primary Sjögren syndrome: a single-center study from Turkey.Turkish journal of medical sciences · 2022Article
- Pancreatic Cancer and Primary Sjögren's Syndrome: A Case Report.Case reports in rheumatology · 2021Article
- Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Sjögren syndrome (pSS) is usually a mild disease, but serious complications such as non-Hodgkin lymphoma-and hypothetically other malignancies-may develop. The aim of this study was to evaluate both overall and specific incidence of cancer in a cohort of patients with pSS compared to the expected incidence in general population of Argentina. Retrospective analytic study of pSS patients fulfilling American-European Consensus Group (AECG) criteria, followed from the time of their diagnosis until the end of the study, death, loss of follow- up, or being given a diagnosis of cancer. Cancer incidence for the general population was obtained from GLOBOCAN 2018, and demographic information was obtained from the national institute for statistics and census. Age- and sex-specific Standardized Incidence Ratio (SIR) were then calculated. One hundred fifty-seven patients, with a mean age of 57.8 years (SD 18.3), were included. Mean patient follow-up duration was 7.37 years (SD 4.2), contributing to a total of 1158 patient/years. Fifteen patients developed a malignancy during follow-up. Cancer incidence for pSS patients was compared with the general population's incidence through SIRs. Female patient's SIRs for overall cancer was 4.17 (95% CI 2.30-6.87), non-Hodgkin lymphoma 41.40 (95% CI 10.12-102.1), multiple myeloma 41.49 (95% CI 1.14-167.28), tongue cancer 44.4 (95% CI 1.23-177.31), uterus cancer 8.39 (95% CI 0.19-40.73), lung cancer 4.51 (95% CI 0.1-22.16), and breast cancer 3.76 (95% CI 1.04-9.45). An increased overall cancer risk, and particularly for non-Hodgkin lymphoma, multiple myeloma, breast cancer and tongue cancer was observed in female pSS patients compared to control group.
Indexed as
Identifiers
31471716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.